QC
AMLX icon

Quadrature Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Quadrature Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,465
Closed -$187K – 1341
2025
Q4 		$187K Sell
15,465
-12,821
-45% -$174K ﹤0.01% 990
2025
Q3 		$384K Sell
28,286
-1,144
-4% -$10.8K ﹤0.01% 606
2025
Q2 		$188K Buy
29,430
+16,686
+131% +$81.2K ﹤0.01% 823
2025
Q1 		$45K Buy
+12,744
New +$45.4K ﹤0.01% 982

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Quadrature Capital's AMLX Position: Q1 2026 in Review

Quadrature Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 15,465 shares — an estimated $187K sold.

Quadrature Capital first reported a position in AMLX in Q1 2025 and held it in 4 quarters. The position peaked at $384K in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Quadrature Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 15,465 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $187K.
  • Quadrature Capital first reported a position in Amylyx Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Quadrature Capital's Amylyx Pharmaceuticals position peaked at $384K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.